The UK government has taken the first step in moving the Accelerated Access Review forward while it still works on its full response to the review.
The UK government said today it was still working on its long-awaited response to the Accelerated Access Review, but has in the meantime taken the first step in moving the AAR forward by investing £86m in funds to help the life sciences industry get innovative products to patients faster.
Up to £6m of the £86m package will be used over the next three years to support SMEs with innovative...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
